Transforming life for patients with Parkinson’s disease
Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.
Two clinical phase II candidates
Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >
Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >
Proprietary technology platform
The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >
We’re looking for an Analytical Chemist to join our team!
IRLAB’s annual report for 2020 is now available on the company’s websiteApril 15, 2021
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the annual report for 2020 is published on www.irlab.se. In addition, the company’s website has been visually updated.Read More >